RE:Scale of purchase????west coast....in context of your entertainment..
The answer is based 100% on $$$$
For Onc the $$ comes from potential Pelareorep sales.
I know next to zero about cancer drug costs.
RBC does however have a $5billion annual " income" from one Pela cancer type.
we are now looking at potentially Two, maybe more.
RBC then goes on to use present value calculations of that forward estimated income.
arriving at the lowest of all analysts being $6.50/ share.
They do add " with a $18/ps upside on additional news &/ or a partnership".
none of the analysts have ever mentioned a buy- out target ( not directly).
one analyst does give a " comparables" table. Showing various similar companies.
Onc is way way , underpriced right now.
A factor of tenX gets us near $1.6 billion.
even that would be very low compared to other buyouts